Allocation Policy Implementation During a Severe Chemotherapy Shortage - Takeaways - MDSpire

Implementing Drug Allocation Policies Amid a Severe Chemotherapy Shortage

By
Eric C. Blackstone
Yating Wang
Eno-Abasi Inyang
Andrew G. Shuman
Michael Casey
Gregory A. Abel
Andrew Hantel
October 19, 2026

Jama Network Open

Share

1

A 2023 manufacturing halt after an FDA quality inspection caused a severe US carboplatin shortage.
2

DFCI rationed carboplatin from June 1 through July 17, 2023, across its main and 6 regional campuses.
3

A multidisciplinary working group developed and implemented DFCI’s allocation policy and communication plans.
4

The policy assigned patients to 5 priority categories using ethical criteria, with carboplatin intended for categories 1 through 3.
5

The retrospective study evaluated policy implementation and whether clinical or demographic factors beyond allocation criteria were associated with actual allocation decisions.

Original Source(s)

Jama Network Open

Allocation Policy Implementation During a Severe Chemotherapy Shortage

by Eric C. Blackstone, Yating Wang, Eno-Abasi Inyang, Andrew G. Shuman, Michael Casey, Gregory A. Abel, Andrew Hantel
October 19, 2026

Related Content

Head And Neck

Depth of Invasion as a Predictor of Contralateral Nodal Metastasis in Lateralized Oral Tongue Squamous Cell Carcinomas

Dana-Farber

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

October 15, 2026
1 min

Journal Of Surgical Oncology

Association of Adjuvant Radiotherapy De-Escalation With Outcomes Following Oncoplastic Breast-Conserving Surgery